[Therapy of coronary heart disease using Cormelian-Digotab. Results of a double blind study].
D001381:Azepines / Q000494:pharmacology / Q000627:therapeutic use*; D001565:Benzoates / Q000494:pharmacology / Q000627:therapeutic use; D001663:Bilirubin / Q000097:blood; D001786:Blood Glucose; D001794:Blood Pressure / Q000187:drug effects; D001799:Blood Sedimentation; D002784:Cholesterol / Q000097:blood; D003326:Coronary Circulation / Q000187:drug effects; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D004077:Digoxin / Q000494:pharmacology / Q000627:therapeutic use*; D004338:Drug Combinations; D004341:Drug Evaluation; D004361:Drug Tolerance; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D000637:Transaminases / Q000097:blood; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use*
D001381:Azepines; D001565:Benzoates; D001786:Blood Glucose; D004338:Drug Combinations; D014665:Vasodilator Agents; D004077:Digoxin; D002784:Cholesterol; D007770:L-Lactate Dehydrogenase; D000637:Transaminases; D001663:Bilirubin
Zur Therapie der koronaren Herzkrankheit mit Cormelian-Digotab. Ergenbnis einer Doppelblind-Studie